A living WHO guideline on drugs for covid-19 (2020-2023)

作者：Arnav Agarwal, Beverley J. Hunt, Miriam Stegemann, Bram Rochwerg, François Lamontagne, Reed Siemieniuk, Thomas Agoritsas, Lisa Askie, Lyubov Lytvyn, Yee‐Sin Leo, Helen Macdonald, Linan Zeng, Ahmed Alhadyan, Al-Maslamani Muna, Wagdy Amin, André Ricardo Araújo da Silva, Diptesh Aryal, Fabián Alberto Jaimes Barragán, Frédérique Jacquerioz Bausch, Erlina Burhan, Carolyn S. Calfee, Maurizio Cecconi, Binila Chacko, Duncan Chanda, Vu Quoc Dat, An De Sutter, Bin Du, Stephen B. Freedman, Heike Geduld, Patrick O. Gee, Muhammad Mohsin Haider, Matthias Götte, Nerina Harley, Madiha Hashmi, David S.C. Hui, Mohamed Ismail, Fyezah Jehan, Sushil Kumar Kabra, Seema Kanda, Yae‐Jean Kim, Niranjan Kissoo, Sanjeev Krishna, Krutika Kuppalli, Arthur Kwizera, Marta Lado Castro-Rial, Thiago Lisboa, Rakesh Lodha, Imelda Mahaka, Hela Manai, Marc Mendelson, Giovanni Battista Migliori, G Miño, Emmanuel Nsutebu, Jessica Peter, Jacobus Preller, N. Pshenichnaya, Nida Qadir, Shalini Sri Ranganathan, Pryanka Relan, Jamie Rylance, Saniya Sabzwari, Rohit Sarin, Manu Shankar‐Hari, Michael Sharland, Yinzhong Shen, João Paulo Souza, Ronald Swanstrom, Tshokey Tshokey, Sebastián Ugarte, Timothy M. Uyeki, Evangelina Vázquez Curiel, Sridhar Venkatapuram, Dubula Vuyiseka, Ananda Wijewickrama, Lien Tran, Dena Zeraatkar, Jessica J Bartoszko, Long Ge, Romina Brignardello‐Petersen, Andrew Owen, Gordon Guyatt, Janet Dı́az, Letícia Kawano-Dourado, Michael Jacobs, Per Olav Vandvik · 发表于：BMJ · 年份：2020 · DOI：10.1136/bmj.m3379 · 被引用次数：1095 · 研究领域：COVID-19 Clinical Research Studies、Parasitic Diseases Research and Treatment、Pharmacological Receptor Mechanisms and Effects

Updates: This is the fourteenth version (thirteenth update) of the living guideline, replacing earlier versions (available as data supplements). New recommendations will be published as updates to this guideline. Clinical question: What is the role of drugs in the treatment of patients with covid-19? Context: The evidence base for therapeutics for covid-19 is evolving with numerous randomised controlled trials (RCTs) recently completed and underway. Emerging SARS-CoV-2 variants and subvariants are changing the role of therapeutics. What is new?: The guideline development group (GDG) defined 1.5% as a new threshold for an important reduction in risk of hospitalisation in patients with non-severe covid-19. Combined with updated baseline risk estimates, this resulted in stratification into patients at low, moderate, and high risk for hospitalisation. New recommendations were added for moderate risk of hospitalisation for nirmatrelvir/ritonavir, and for moderate and low risk of hospitalisation for molnupiravir and remdesivir. New pharmacokinetic evidence was included for nirmatrelvir/ritonavir and molnupiravir, supporting existing recommendations for patients at high risk of hospitalisation. The recommendation for ivermectin in patients with non-severe illness was updated in light of additional trial evidence which reduced the high degree of uncertainty informing previous guidance. A new recommendation was made against the antiviral agent VV116 for patients with non-severe and wi...